Tariq Haddad, MD
Cardiovascular Disease · Falls Church, VANPI 1487698965
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Novartis at 30.8% of the total. Reporting peaked in 2023 at $7,787 and has fallen 78.2% since, to $1,699 in 2025. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $104.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$6K
- Eli Lilly$4K
- AstraZeneca$3K
- Merck$2K
- Janssen Research & Development, LLC$1K
- Bayer$1K
- plus $1K from 19 others
Across 409 payments — averaging $19,647 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4.6M
- Amgen$1.3M
- Eli Lilly$1M
- AstraZeneca$612K
- Regeneron$271K
- Janssen Research & Development, LLC$53K
- plus $186K from 6 others
What the payments were for
- Consulting fees$2,55814%
- Travel & lodging$10,07356%
- Food & beverage$5,46130%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 44 | $5,572 |
| Eli Lilly | 30 | $4,001 |
| AstraZeneca | 21 | $3,001 |
| Merck | 12 | $1,800 |
| Janssen Research & Development, LLC | 10 | $1,214 |
| Bayer | 11 | $1,186 |
| Abbott | 2 | $257 |
| E.r. Squibb & Sons, L.L.C. | 7 | $226 |
| Edwards Lifesciences | 1 | $150 |
| Pfizer | 3 | $142 |
| Amgen | 6 | $89 |
| Johnson & Johnson | 4 | $76 |
| Novo Nordisk | 3 | $63 |
| Astrazeneca AB | 2 | $40 |
| Boston Scientific | 2 | $32 |
| Abiomed | 2 | $32 |
| Kestra Medical Technology Services, Inc. | 1 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $29 |
| Boehringer Ingelheim | 1 | $26 |
| Recor Medical Inc | 1 | $26 |
| Amarin Pharma, Inc. | 2 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$150
- MitraClip$148
- VYNDAQEL$123
- CAMZYOS$116
- FARXIGA$108
How this compares
$18,098 in reported general payments places this provider in the 90th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 102 | $148,185 |
| Repatha SureclickEvolocumab | 34 | $52,810 |
| EntrestoSacubitril/Valsartan | 30 | $44,803 |
| XareltoRivaroxaban | 30 | $40,730 |
| FarxigaDapagliflozin Propanediol | 33 | $39,810 |
| JardianceEmpagliflozin | 27 | $35,277 |
| Praluent PenAlirocumab | 25 | $30,677 |
| BrilintaTicagrelor | 11 | $14,609 |
| Ezetimibe | 130 | $3,839 |
| Rosuvastatin Calcium | 198 | $3,827 |
| Atorvastatin Calcium | 197 | $2,639 |
| Ranolazine ErRanolazine | 16 | $2,019 |
| Metoprolol Succinate | 138 | $1,982 |
| Valsartan | 23 | $1,430 |
| Losartan Potassium | 90 | $911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $148,185102 claims |
| AstraZenecaFarxiga, Brilinta | $3,001 | $54,41944 claims |
| NovartisEntresto | $5,572 | $44,80330 claims |
| Johnson & JohnsonXarelto | $76 | $40,73030 claims |
| Boehringer IngelheimJardiance | $26 | $35,27727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Falls Church
- Alexander TruesdellFalls Church$167K
- Christopher OconnorFalls Church$161K
- Joseph KreppFalls Church$74K
- Behnam TehraniFalls Church$58K
- Mitchell PsotkaFalls Church$35K
- Leonard IlkhanoffFalls Church$14K
- Shashank SinhaFalls Church$12K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.